Skip to main content
British Journal of Pharmacology logoLink to British Journal of Pharmacology
. 1983 May;79(1):37–43. doi: 10.1111/j.1476-5381.1983.tb10492.x

Comparison of two calcium antagonists, verapamil and fendiline, in an experimental model of myocardial ischaemia mimicking classical angina on effort.

V Csik, L Szekeres, E Udvary
PMCID: PMC2044837  PMID: 6871551

Abstract

1 The effects of verapamil (0.15/kg) and fendiline (3 mg/kg) were studied in anaesthetized, thoracotomised dogs with a critical constriction of the left anterior descending coronary artery, paced in excess of the initial rate by 60-70 beats/min. Epicardial ST-segment elevation and changes in lactate uptake were used to assess the severity of myocardial ischaemia. 2 Both drugs prevented the ST-segment elevation and the reduced lactate uptake that resulted from atrial pacing. 3 The anti-ischaemic effect of fendiline is mainly due to its negative chronotropic action, whereas that of verapamil is due in part to bradycardia and in part to the reduced preload and afterload. In addition, both agents increase coronary flow to the ischaemic area and thus improve the myocardial oxygen supply/oxygen requirement ratio.

Full text

PDF

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Atterhög J. H., Ekelund L. G. Haemodynamic effects of intravenous verapamil at rest and during exercise in subjectively healthy middle-aged men. Eur J Clin Pharmacol. 1975 Jun 13;8(5):317–322. doi: 10.1007/BF00562656. [DOI] [PubMed] [Google Scholar]
  2. Berdeaux A., Coutte R., Giudicelli J., Boissier J. Effects of verapamil on regional myocardial blood flow and ST segment. Role of the induced bradycardia. Eur J Pharmacol. 1976 Oct;39(2):287–294. doi: 10.1016/0014-2999(76)90138-2. [DOI] [PubMed] [Google Scholar]
  3. Carlens P. Effect of intravenous verapamil on exercise tolerance and left ventricular function in patients with severe exertional angina pectoris. J Cardiovasc Pharmacol. 1981 Jan-Feb;3(1):1–10. doi: 10.1097/00005344-198101000-00001. [DOI] [PubMed] [Google Scholar]
  4. Ferlinz J., Turbow M. E. Antianginal and myocardial metabolic properties of verapamil in coronary artery disease. Am J Cardiol. 1980 Dec 1;46(6):1019–1026. doi: 10.1016/0002-9149(80)90361-6. [DOI] [PubMed] [Google Scholar]
  5. Kaltenbach M. Medikamentöse Therapie der koronaren Herzkrankheit. Arzneimittelforschung. 1977;27(3A):703–707. [PubMed] [Google Scholar]
  6. Pedersen O. L. Calcium blockade as a therapeutic principle in arterial hypertension. Clinical aspects and experimental studies on isolated vessels from spontaneously hypertensive rats and normotensive man. Acta Pharmacol Toxicol (Copenh) 1981;49 (Suppl 2):1–31. doi: 10.1111/j.1600-0773.1981.tb03365.x. [DOI] [PubMed] [Google Scholar]
  7. Strauer B. E. Inotropic effects of Nifedipine: a new coronary dilating agent. Int J Clin Pharmacol. 1974 Mar;9(2):101–107. [PubMed] [Google Scholar]
  8. Subramanian V. B., Lahiri A., Paramasivan R., Raftery E. B. Verapamil in chronic stable angina. A controlled study with computerized multistage treadmill exercise. Lancet. 1980 Apr 19;1(8173):841–844. doi: 10.1016/s0140-6736(80)91351-3. [DOI] [PubMed] [Google Scholar]
  9. Szekeres L., Csik V., Udvary E. Nitroglycerin and dipyridamole on cardiac metabolism and dynamics in a new experimental model of angina pectoris. J Pharmacol Exp Ther. 1976 Jan;196(1):15–28. [PubMed] [Google Scholar]
  10. Szekeres L., Csik V., Udvary E. The effect of beta-adrenoceptor blocking drugs on free fatty acid and glucose utilization of the isolated canine heart with normal and restricted flow in the presence and absence of noradrenaline. Acta Biol Med Ger. 1978;37(5-6):817–820. [PubMed] [Google Scholar]
  11. da Luz P. L., Monteiro de Barros L. F., Leite J. J., Pileggi F., Décourt L. V. Effect of verapamil on regional coronary and myocardial perfusion during acute coronary occlusion. Am J Cardiol. 1980 Feb;45(2):269–275. doi: 10.1016/0002-9149(80)90645-1. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Pharmacology are provided here courtesy of The British Pharmacological Society

RESOURCES